scorecardresearch
Follow Us:
Saturday, May 28, 2022

Bharat Biotech’s intranasal Covid booster dose trials get DCGI nod

The approval comes soon after Covaxin and Serum Institute of India's Covishield were cleared for sale in the market.

By: Express Web Desk | New Delhi |
Updated: January 28, 2022 3:39:17 pm
The trials will be conducted at nine different sites in India | Representational image/Getty images

Bharat Biotech, the maker of Covaxin, on Friday obtained approval from the Drugs Controller General of India (DCGI) for conducting trials of its intranasal booster doses against Covid-19 (BBV154).

According to news agency ANI, the trials will be conducted at nine different sites in India.

“The Phase-3 clinical trial should be conducted as per protocol multi-centre study to compare immunogenicity and safety of BBV154 with Covaxin,” the letter issued by the DCGI said.

An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.

Best of Express Premium

‘Monetisation’ axed, MeitY’s fresh draft to ‘encourage’ cos to share non-...Premium
SC directions on sex workers: history of the case, and where it stands nowPremium
Cruise drug raid case: One officer went rogue, agency looked other wayPremium
Hindus and Muslims must give up rigid positions on contested places of wo...Premium

Bharat Biotech had last month sought the drug regulator’s approval to conduct phase 3 trials of the nasal vaccine. The approval comes soon after Covaxin and Serum Institute of India’s Covishield were cleared for sale in the market.

For all the latest India News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement